TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04818411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy treatment with the Stabilization exercises
Description: The program was based on specific training of the transversely oriented abdominal muscles with coactivation of the lumbar multifidus at the lumbosacral region, training of the gluteus maximus, the latissimus dorsi, the oblique abdominal muscles, the erector spinae, the quadratus lumborum, and the hip adductors and abductors. Initially, we focused on the specific contraction of the transversely oriented abdominal muscles. After approximately 2 weeks, loading was progressively increased throughout the intervention period. The women were required to exercise for 30 to 60 minutes, 3 days a week, for 3-4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy treatment + High-velocity thrust manipulation
Description: : For high-velocity thrust technique, a modified Chicago technique was used. For this procedure, the lumbopelvic region was targeted. The side to be treated was chosen, based on the subject's report of her most symptomatic side. The physical therapist, performed passively side bend the subject toward the painful side, rotate the upper body in the direction opposite to the side bending, and then deliver a quick posterior and inferior thrust at a grade V including a small-amplitude/high-velocity therapeutic movement. A maximum of 2 attempts per side was permitted if no pop was heard following the first attempt. If the subject showed improvement of 50% or less after the first treatment, the intervention was categorized as a failure, the examination and intervention were repeated, and the subjects were asked to return 2 to 4 days later. If the subject showed greater than 50% improvement, the intervention was categorized as a success, and study participation was concluded.
Study: NCT04313634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Fisetin will be supplied in 100 mg capsules to be administered orally
Study: NCT02513017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Control Instructions and Sleep Restriction Therapy
Description: Please refer to arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Control Instructions and Sleep Restriction Therapy
Description: Please refer to arm/group descriptions.
Study: NCT00986167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
Study: NCT03560427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg
Description: Patients will receive duloxetine, 60 mg tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
Study: NCT02415400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin K antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid placebo
Study: NCT02909777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-907
Study: NCT05216172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00628771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy Plus (CP+)
Description: The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care includes standard individual prenatal care and no prenatal group sessions.
Study: NCT01757964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriotherapy
Study: NCT01293448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon Ablation
Description: Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)
Study: NCT02797925

Intervention type: OTHER
Intervention: Training
Description: Long slow strength training of the tendon for 3 months to improve function
Study: NCT00868023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 Next DPI
Description: CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster BDP/Formoterol
Description: BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 Next DPI
Description: CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster BDP/Formoterol
Description: BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00652665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Tablets, 20mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARAVA
Description: Tablets, 20mg,single-dose
Study: NCT03689322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WBV + IMT
Description: The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WBV + IMTsham
Description: The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: WBVsham + IMTsham
Description: Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
Study: NCT01140191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396
Description: Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
Study: NCT04358731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NmCV-5
Description: The NmCV-5 is a fixed-combination available as the lyophilized powder containing meningococcal groups A and X polysaccharides conjugated to tetanus toxoid and meningococcal groups C, W and Y polysaccharides conjugated to CRM197 protein. The vaccine will be reconstituted with normal saline just prior to administration.~The NmCV-5 lyophilized powder component contains sucrose, sodium citrate and trometamol as excipients. This component is presented as a freeze-dried powder in a single dose vial. No preservative or adjuvant is present in the vaccine.~The normal saline diluent is a sterile clear colorless liquid in a single dose glass ampoule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: The control vaccine is the licensed meningococcal serogroups ACYW conjugate vaccine (Menactra), manufactured by Sanofi Pasteur Incorporated. Menactra is supplied as a single 0.5 mL dose formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4 mcg each of meningococcal A, C, Y, and W polysaccharides conjugated to approximately 48 mcg of diphtheria toxoid protein carrier. No preservative or adjuvant is added during manufacture.
Study: NCT00549926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT00981591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
Study: NCT00700401

Intervention type: DRUG
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms/week sc for 24 weeks

Intervention type: DRUG
Intervention: ribavirin [Copegus]
Description: 800mg po daily for 24 weeks
Study: NCT04371900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)
Description: M-CARES randomized vouchers for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred from March 4, 2019, forward.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)
Description: M-CARES randomized vouchers for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after November 4, 2019.
Study: NCT03069222

Intervention type: OTHER
Intervention: Standard Rehabilitative Treatment
Description: The patients will participate in standard but comprehensive SCI specific rehabilitation therapy provided by the SCI program at KIR. The therapy consists of 3 hours per day, 5 days a week. Motor function therapy includes standardized procedures for range of motion, passive and active muscle activities, and therapies to improve mobility. The treatment program for the enrolled patients will be standardized by Dr. Kirshblum, Director of the SCI program at KIR and a Co-Investigator of the study. Patients usually receive 4 weeks of rehabilitation treatment; however, if any of them are discharged earlier from KIR, their out-patient treatment activities will be monitored and the patients will be tested based on the planned schedule.
Study: NCT01650259

Intervention type: DRUG
Intervention: OAD
Description: OAD except Trazenta tablets

Intervention type: DRUG
Intervention: Trazenta
Description: Linagliptin
Study: NCT00936858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study: NCT01419561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine 600 mg will be administered orally 4 times a day or i.v. at 300 mg every 6 hours for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Liposomal doxorubicin (20 mg/m2) will be administered i.v. over 1 hour at day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganiclovir
Description: Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (375 mg/m2) will be admnistered i.v. at 50 mg/hr up to 100 mg/hr at day 1 of the first cycle and at 100mg/hr up to 400 mg~/hr at day 1 of following cycles.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Therapies
Description: Standard of Care drugs

Intervention type: OTHER
Group type: OTHER
Intervention: Cohort 1
Description: Participants who are infected with KSHV who meet criteria for inflammatory cytokine syndrome (KICS)
Study: NCT03588676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg Melatonin
Study: NCT01164735

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03588676

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg Placebo capsule
Study: NCT01562470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cellulite reduction cream
Description: 1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
Study: NCT02540707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: solifenacin
Description: solifenacin 5 mg per day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: mirabegron 25 mg per day for 12 weeks
Study: NCT04618913

Intervention type: DRUG
Intervention: Apixaban
Description: Anticoagulant

Intervention type: DRUG
Intervention: Apixaban
Description: Anticoagulant

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Anticoagulant

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Anticoagulant

Intervention type: DRUG
Intervention: Edoxaban
Description: Edoxaban

Intervention type: DRUG
Intervention: Edoxaban
Description: Edoxaban

Intervention type: DRUG
Intervention: Dabigatran
Description: Dabigatran

Intervention type: DRUG
Intervention: Dabigatran
Description: Dabigatran

Intervention type: DRUG
Intervention: VKA
Description: Vitamin K antagonist

Intervention type: DRUG
Intervention: VKA
Description: Vitamin K antagonist

Intervention type: DRUG
Intervention: LMWH
Description: Low Molecular Weight Heparin

Intervention type: DRUG
Intervention: LMWH
Description: Low Molecular Weight Heparin
Study: NCT03607305

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BP limb 70cm
Description: Performance of RYGB with a BP limb of 70cm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BP limb 120cm
Description: Performance of RYGB with a BP limb of 120cm
Study: NCT04757753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ready-to-use root canal sealer: PA1704
Description: The participant will be treated with the ready-to-use root canal sealer (PA1704) in combination with gutta percha.

Intervention type: DEVICE
Group type: OTHER
Intervention: root canal sealer: BioRoot™ RCS
Description: The participant will be treated with BioRoot™ RCS sealer in combination with gutta percha.
Study: NCT00318266

Intervention type: DEVICE
Intervention: Nuclear Matrix Protein 22 Urine sample kit
Description: Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
Study: NCT01968616

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab, 0.5mg, Intravitreal
Study: NCT03721900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHX-001 Active low dose
Description: ketamine transdermal patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: transdermal patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHX-001 Active High dose
Description: ketamine transdermal patch
Study: NCT01350388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: 80 mg/day of febuxostat for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet per day for 24 weeks
Study: NCT04560192

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based Emotion regulation therapy (MBERT) - Treatment as usual (TAU)
Description: 1. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.~2. Waiting period with TAU.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU) - Mindfulness based Emotion regulation therapy (MBERT)
Description: 1. Waiting period with TAU.~2. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.
Study: NCT00789399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux
Description: Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous equivolume isotonic saline
Study: NCT00580047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: 4mg IV Annually

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium with vitamin D
Description: 1200 mg Calcium with 800 International Units of vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70mg weekly
Study: NCT02820298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Bexagliflozin tablet, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Bexagliflozin tablet, 20 mg
Study: NCT01707498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scanning device
Description: Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RoBIK Brain-Computer Interface
Description: Patients will be asked to spell a text with the BCI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RoBIK Brain-Computer Interface
Description: Patients will be asked to spell a text with the BCI
Study: NCT03392779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 25 mg
Description: ZSP1601 tablet administered orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 25mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 50 mg
Description: ZSP1601 tablet administered orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 50 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 100 mg
Description: ZSP1601 tablets administered orally once daily in the fasting state
Study: NCT01700751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin